Clinical Trials Logo

Leukemia, Lymphoid clinical trials

View clinical trials related to Leukemia, Lymphoid.

Filter by:

NCT ID: NCT04823091 Recruiting - Clinical trials for T Cell Non-Hodgkin Lymphoma

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

Start date: April 15, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in patients with relapsed or refractory T lymphoid malignancies.

NCT ID: NCT04817761 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

SPARK-ALL: Calaspargase Pegol in Adults With ALL

Start date: July 7, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia.

NCT ID: NCT04809467 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

topMIND
Start date: September 16, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely combined at the recommended Phase 2 dose (RP2D) and dosing regimen that was established for each of the 2 compounds as a treatment option for adult participants with R/R B-cell malignancies.

NCT ID: NCT04808570 Terminated - Clinical trials for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start date: June 5, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

NCT ID: NCT04806035 Active, not recruiting - Follicular Lymphoma Clinical Trials

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Start date: April 23, 2021
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the recommended phase 2 dose (RP2D) and characterize the safety profile of TG-1801. As per protocol v3.0, ublituximab will be discontinued.

NCT ID: NCT04796688 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

Start date: March 10, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of universal chimeric antigen receptor-modified AT19 cells in patients with relapsed or refractory hematological malignancies.

NCT ID: NCT04796675 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Start date: April 10, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of anti-CD19 chimeric antigen receptor(CAR)-modified NK cells(CAR-NK-CD19) in patients with relapsed or refractory hematological malignancies.

NCT ID: NCT04794296 Recruiting - Childhood ALL Clinical Trials

Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP

LALGFA2019
Start date: November 15, 2021
Phase:
Study type: Observational [Patient Registry]

The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.

NCT ID: NCT04792593 Recruiting - B-ALL Clinical Trials

Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Start date: December 3, 2020
Phase: N/A
Study type: Interventional

This study is an open, dose-escalating clinical study, taking patients with relapsed or refractory acute lymphoblastic leukemia as the test subjects, including mouse-derived CAR-T treatment failure or relapse, or for any reason cannot bridge the transplant r/r B-ALL.

NCT ID: NCT04788472 Recruiting - Clinical trials for B-Cell Acute Lymphoblastic Leukemia, Adult

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

Start date: March 5, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Clinical Trial for the Safety and Efficacy of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia